Author(s): Gelderman MP, Vostal JG
Abstract Share this page
Abstract Novel red blood cell and platelet transfusion products may be synthetic or may result from modifications to approved collection, processing, and storage procedures for existing cellular products. They must be reviewed and evaluated by the Food and Drug Administration before being legally marketed in the United States to ensure they are safe, pure, and potent. This article reviews the literature and discusses the current and future state of cellular transfusion products. Published by Elsevier Inc.
This article was published in Clin Lab Med
and referenced in